MICA: Towards targeted treatment for complex regional pain syndrome through determination of the underlying molecular mechanisms

MICA:通过确定潜在的分子机制来靶向治疗复杂的区域疼痛综合征

基本信息

  • 批准号:
    MR/W027240/1
  • 负责人:
  • 金额:
    $ 49.28万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2022
  • 资助国家:
    英国
  • 起止时间:
    2022 至 无数据
  • 项目状态:
    未结题

项目摘要

Complex regional pain syndrome (CRPS) is a chronic pain condition that can occur after an injury, such as a fracture and results in localised pain and swelling. CRPS spontaneously resolves within a year in 20-30% of cases, but after this time it becomes chronic and rarely improves. Treatment options for CRPS patients, as with many other forms of chronic pain, are very limited, untargeted, and often have significant side effects. It is, therefore, important to understand why CRPS develops and the underlying mechanisms involved in order to try and develop more effective drugs targeting pain and inflammation and improve lives of those living with CRPS.We can often gain insight into why a disease develops by looking at changes found in genes (mutations), which in turn helps design new drugs, such as pain killers (analgesics). For example, changes in a gene called nerve growth factor, were found in a family unable to feel pain (inherited as a very rare disease), and this led to the discovery of a new class of analgesics that is particularly helpful against arthritic pain. We wanted to see if patients with CRPS had mutations in their genes, compared to non-sufferers, which could alter their susceptibility to the condition. We found that CRPS patients were more likely to have mutations in four genes compared to people without CRPS. Each of these mutations was hypothesised to cause alterations of protein function. We, and others, have shown these four genes are expressed in monocytes and/or macrophages (cells that engulf foreign particles and cause inflammation). Importantly, all four genes are linked to the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammatory pathway that senses foreign particles and removes them by causing release of inflammatory molecules and cell death. These data suggest that the NLRP3 inflammasome pathway is likely to be important in the pathology of CRPS. In this proposal we will investigate how the CRPS-mutated genes affect the activity of the NLRP3 inflammasome. In order to do this, we will introduce the gene mutations into a human monocyte cell line (THP-1 cells). Next, we will determine if these mutations alter the activity of the NLRP3 inflammasome by measuring the production of inflammatory molecules and cell death in THP-1 cells. We will validate the THP-1 model by measuring inflammasome activity in cells from healthy individuals with the CRPS-associated mutations. Our next step will be to determine how these changes in NLRP3 inflammasome activity influence pain neuron activation as a method to model the excessive pain seen in CRPS. Lastly, we will test how NLRP3 modulators affect pain and inflammation in order to translate our findings towards the development of new drugs for CRPS. We anticipate our research will lead to the identification of a new class of non-addictive pain-killers that will reduce inflammation and pain to stop the chronic stage of CRPS from developing. This would have very significant effects on pain management, inflammation and the depression, morbidity and mortality that are a consequence of prolonged severe pain.
复杂局部疼痛综合征(CRPS)是一种慢性疼痛状况,可在受伤(如骨折)后发生,并导致局部疼痛和肿胀。在20-30%的病例中,CRPS会在一年内自行消退,但在此之后就会变成慢性疾病,很少好转。与许多其他形式的慢性疼痛一样,慢性疼痛综合征患者的治疗选择非常有限,没有针对性,而且往往有明显的副作用。因此,了解CRPS发展的原因和潜在的机制是很重要的,以便尝试和开发更有效的针对疼痛和炎症的药物,改善CRPS患者的生活。我们通常可以通过观察基因的变化(突变)来了解疾病发展的原因,这反过来又有助于设计新药,例如止痛药。例如,在一个无法感知疼痛的家族(作为一种非常罕见的遗传疾病)中发现了一种叫做神经生长因子的基因的变化,这导致了一种新型止痛药的发现,这种止痛药对关节炎疼痛特别有帮助。我们想看看与非患者相比,CRPS患者的基因是否发生了突变,这可能会改变他们对这种疾病的易感性。我们发现,与没有CRPS的人相比,CRPS患者更有可能在四个基因上发生突变。这些突变中的每一个都被假设会导致蛋白质功能的改变。我们和其他人已经证明,这四种基因在单核细胞和/或巨噬细胞(吞噬外来颗粒并引起炎症的细胞)中表达。重要的是,这四个基因都与NOD-、LRR-和pyrin结构域蛋白3 (NLRP3)炎症通路有关,该通路感知外来颗粒,并通过引起炎症分子的释放和细胞死亡来清除它们。这些数据提示NLRP3炎性体通路可能在CRPS的病理中起重要作用。在本研究中,我们将研究crps突变基因如何影响NLRP3炎症小体的活性。为了做到这一点,我们将基因突变引入人类单核细胞系(THP-1细胞)。接下来,我们将通过测量THP-1细胞中炎症分子的产生和细胞死亡来确定这些突变是否改变了NLRP3炎症小体的活性。我们将通过测量具有crps相关突变的健康个体细胞中的炎性体活性来验证THP-1模型。我们的下一步将是确定NLRP3炎性体活动的这些变化如何影响疼痛神经元的激活,作为模拟CRPS中看到的过度疼痛的方法。最后,我们将测试NLRP3调节剂如何影响疼痛和炎症,以便将我们的发现转化为CRPS新药的开发。我们预计我们的研究将导致鉴定出一类新的非成瘾性止痛药,这种止痛药将减少炎症和疼痛,从而阻止慢性慢性慢性疼痛综合征的发展。这将对疼痛管理,炎症和抑郁,发病率和死亡率产生非常重要的影响这些都是长期剧烈疼痛的后果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Clare Bryant其他文献

Chronic lymphocytic leukemia increases the pool of peripheral blood hematopoietic stem cells and skews differentiation.
慢性淋巴细胞白血病会增加外周血造血干细胞的数量并扭曲分化。
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    7.5
  • 作者:
    A. Santoro;Camelia Andrei;Clare Bryant;Emily F. Calderbank;Alison Wray;J. Baxter;A. Godfrey;E. Laurenti;I. Ringshausen
  • 通讯作者:
    I. Ringshausen
The delayed kinetics of Myddosome formation explains why Aβ aggregates trigger TLR4 less efficiently than LPS
Myddosome 形成的延迟动力学解释了为什么 Aβ 聚集体触发 TLR4 的效率低于 LPS
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bing Li;Prasanna Suresh;Jack Brelstaff;Shekhar Kedia;Clare Bryant;D. Klenerman
  • 通讯作者:
    D. Klenerman
New perspectives and future options for treatment of endotoxemia
  • DOI:
    10.1016/s0737-0806(00)80124-0
  • 发表时间:
    2000-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Clare Bryant
  • 通讯作者:
    Clare Bryant
A mammalian commensal of the oropharyngeal cavity produces antibiotic and antiviral valinomycin in vivo
哺乳动物口咽腔的共生体在体内产生抗生素和抗病毒药物缬氨霉素
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    R. Gaiser;M. Ferrando;Alberto Oddo;Milton C. A. Pereira;X. Guan;F. Molist;Marcela M. Fernandez;Simen Fredriksen;Clare Bryant;D. Petráš;P. Dorrestein;S. Boeren;M. Medema;C. Hill;M. Kleerebezem;P. Baarlen;J. Wells
  • 通讯作者:
    J. Wells

Clare Bryant的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Clare Bryant', 18)}}的其他基金

The molecular basis of viral tolerance in bats
蝙蝠病毒耐受的分子基础
  • 批准号:
    BB/Y003772/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Research Grant
Inflammasome complex organisation in infectious and inflammatory diseases
感染性和炎症性疾病中的炎症小体复合体组织
  • 批准号:
    MR/X000826/1
  • 财政年份:
    2023
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Research Grant
Molecular characterisation of Toll-like receptor 4 biased signalling through the TIR-domain-containing adapter-inducing interferon-beta
通过含有 TIR 结构域的接头诱导干扰素-β 的 Toll 样受体 4 偏向信号传导的分子表征
  • 批准号:
    BB/V000276/1
  • 财政年份:
    2021
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Research Grant
Development of small molecule TLR4 agonists as animal adjuvants
小分子TLR4激动剂动物佐剂的开发
  • 批准号:
    BB/P017363/1
  • 财政年份:
    2017
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Research Grant
Effects of Nod-like receptor activity on protective immunity against Salmonella infection
Nod样受体活性对沙门氏菌感染保护性免疫的影响
  • 批准号:
    BB/K006436/1
  • 财政年份:
    2013
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Research Grant
A mathematical and biophysical analysis of salmonella macrophage interactions
沙门氏菌巨噬细胞相互作用的数学和生物物理分析
  • 批准号:
    BB/H021930/1
  • 财政年份:
    2010
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Fellowship
Characterisation of the Pattern Recognition Receptors required for the development of protective immunity against Salmonella infection
沙门氏菌感染保护性免疫发展所需的模式识别受体的表征
  • 批准号:
    BB/H003916/1
  • 财政年份:
    2009
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Research Grant

相似海外基金

Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal
消灭 HIV:PKC 介导的潜伏期逆转的新概念和有效化合物
  • 批准号:
    10700404
  • 财政年份:
    2023
  • 资助金额:
    $ 49.28万
  • 项目类别:
Enhancing plant growth with novel catalytic "fertiliser" targeted towards the highly inefficient enzyme Rubisco
利用针对效率极低的 Rubisco 酶的新型催化“肥料”促进植物生长
  • 批准号:
    2755354
  • 财政年份:
    2022
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Studentship
Towards Precise Phenotype Discovery of Obstructive Sleep Apnea with a Data-Inclusive Multi-Study Analysis Using the National Sleep Research Resource (NSRR)
使用国家睡眠研究资源 (NSRR) 通过包含数据的多项研究分析来精确发现阻塞性睡眠呼吸暂停的表型
  • 批准号:
    10675011
  • 财政年份:
    2022
  • 资助金额:
    $ 49.28万
  • 项目类别:
Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal
消灭 HIV:PKC 介导的潜伏期逆转的新概念和有效化合物
  • 批准号:
    10652684
  • 财政年份:
    2022
  • 资助金额:
    $ 49.28万
  • 项目类别:
Towards Precise Phenotype Discovery of Obstructive Sleep Apnea with a Data-Inclusive Multi-Study Analysis Using the National Sleep Research Resource (NSRR)
使用国家睡眠研究资源 (NSRR) 通过包含数据的多项研究分析来精确发现阻塞性睡眠呼吸暂停的表型
  • 批准号:
    10516409
  • 财政年份:
    2022
  • 资助金额:
    $ 49.28万
  • 项目类别:
Towards Genome Engineering: Principles of precision in RNA-binding and cDNA-synthesis for a site-specifically targeted non-LTR retroelement
迈向基因组工程:位点特异性靶向非 LTR 逆转录元件的 RNA 结合和 cDNA 合成的精确原理
  • 批准号:
    10377343
  • 财政年份:
    2021
  • 资助金额:
    $ 49.28万
  • 项目类别:
Towards a comprehensive neurometabolic profile in patients with mild cognitive impairment.
为轻度认知障碍患者提供全面的神经代谢特征。
  • 批准号:
    10360721
  • 财政年份:
    2021
  • 资助金额:
    $ 49.28万
  • 项目类别:
Towards a comprehensive neurometabolic profile in patients with mild cognitive impairment.
为轻度认知障碍患者提供全面的神经代谢特征。
  • 批准号:
    10390417
  • 财政年份:
    2021
  • 资助金额:
    $ 49.28万
  • 项目类别:
Towards a comprehensive neurometabolic profile in patients with mild cognitive impairment.
为轻度认知障碍患者提供全面的神经代谢特征。
  • 批准号:
    10602399
  • 财政年份:
    2021
  • 资助金额:
    $ 49.28万
  • 项目类别:
MultiViewPortal: Towards a Scalable Web Application for Multiview Learning
MultiViewPortal:面向多视图学习的可扩展 Web 应用程序
  • 批准号:
    10827749
  • 财政年份:
    2021
  • 资助金额:
    $ 49.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了